home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Renewable Cell Therapy For Diabetes Inches Closer

 
  February, 21 2008 9:39
your information resource in human molecular genetics
 
     
Researchers have converted human embryonic stem (ES) cells into cells that release insulin in response to glucose and alleviate a diabetes-like condition in mice. With further research and development, this approach, reported online in Nature Biotechnology, could lead to a renewable source of cells for the treatment of diabetes.

Type 1 diabetes and some forms of type 2 diabetes involve the loss of pancreatic 'beta' cells, which regulate blood glucose (sugar) levels by releasing insulin. In previous work, Emmanuel Baetge and colleagues described a method for driving human ES cells part of the way along the developmental path of the pancreas to becoming beta cells. The resulting cells could not carry out the key function of mature beta cells, which is to release insulin in response to glucose.

In their new study, Baetge's team shows that if immature pancreatic cells derived from human ES cells are transplanted into mice, in 1-3 months they will develop into glucose-responsive, insulin-secreting cells. These in vivo-matured cells are able to regulate the blood glucose levels of mice whose own beta cells have been destroyed by a chemical treatment - an animal model that mimics some forms of diabetes. The blood glucose control achieved is of similar effectiveness to that obtained by transplanted human islets.

The principle of treating diabetes by transplantation of pancreatic beta cells (within islets) has been demonstrated using the so-called Edmonton protocol. Thus far, this therapy has relied on cells from donor pancreases. Because the supply of such cells is very limited, there is great interest in developing alternative sources of beta cells, including cells derived from human ES cells.

Author contact:

Emmanuel Baetge (Novocell Inc, San Diego, CA, USA)
E-mail: ebaetge@novocell.com

Abstract available online.

(C) Nature Biotechnology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.